Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25157109 | 0.81 | ALDH1A1 (0.33) | HSD17B10ALDH1A1 | |
| SCHEMBL19781524 | 0.78 | L3MBTL1 (0.49) | L3MBTL1RXFP1HSD17B10PRNPHTR6 | |
| SCHEMBL29956028 | 0.77 | ALDH1A1 (0.33) | HSD17B10ALDH1A1HTR6 | |
| SCHEMBL19781523 | 0.75 | L3MBTL1 (0.46) | L3MBTL1RXFP1HSD17B10PRNPHTR6 | |
| SCHEMBL31155609 | 0.72 | L3MBTL1 (0.44) | L3MBTL1RXFP1HSD17B10PRNPHTR6 | |
| SCHEMBL1870362 | 0.71 | PIK3CB (0.32) | ALDH1A1TRPA1 | |
| SCHEMBL22438547 | 0.71 | L3MBTL1 (0.42) | L3MBTL1RXFP1PRNPHTR6PABPC1 | |
| SCHEMBL29955904 | 0.71 | ERN1 (0.34) | HSD17B10ALDH1A1TRPA1 | |
| SCHEMBL24632396 | 0.71 | ATM (0.31) | ALDH1A1 | |
| SCHEMBL1047966 | 0.70 | ALDH1A1 (0.41) | HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741932-B2 | Imidazopyridine derivatives | Piramal Enterprises Limited (IN) | 2014-06-03 | — | — | US | disclosed |
| US-20120232072-A1 | IMIDAZOPYRIDINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-09-13 | — | — | US | disclosed |
| WO-2011055320-A1 | IMIDAZOPYRIDINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232072-A1 | IMIDAZOPYRIDINE DERIVATIVES | IL6, IL6ST, STAT3 | L3MBTL1 4847/4885RXFP1 1653/4885HSD17B10 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.